Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools

• Published in: Genes Vol. 8; no. 10; p. 217
• Main Authors: Martínez-Montiel, Nancy, Anaya-Ruiz, Maricruz, Pérez-Santos, Martín, Martínez-Contreras, Rebeca D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05-10-2017; MDPI
• Subjects: Alternative splicing; Breast cancer; Eukaryotes; Isoforms; Review; breast cancer; therapeutics; expression; alternative splicing; prognosis
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes8100217

Alternative splicing is a key molecular mechanism now considered as a hallmark of cancer that has been associated with the expression of distinct isoforms during the onset and progression of the disease. The leading cause of cancer-related deaths in women worldwide is breast cancer, and even when the role of alternative splicing in this type of cancer has been established, the function of this mechanism in breast cancer biology is not completely decoded. In order to gain a comprehensive view of the role of alternative splicing in breast cancer biology and development, we summarize here recent findings regarding alternative splicing events that have been well documented for breast cancer evolution, considering its prognostic and therapeutic value. Moreover, we analyze how the response to endocrine and chemical therapies could be affected due to alternative splicing and differential expression of variant isoforms. With all this knowledge, it becomes clear that targeting alternative splicing represents an innovative approach for breast cancer therapeutics and the information derived from current studies could guide clinical decisions with a direct impact in the clinical advances for breast cancer patients nowadays.